What Hims and Hers’ revenue and user growth could mean for the future of D2C healthcare

Posted On // Leave a Comment
 
Insider Intelligence
 

What Hims and Hers' revenue and user growth could mean for the future of D2C healthcare

Direct-to-consumer (D2C) telehealth firm Hims & Hers' revenues grew 83% YoY from 2020 to 2021, and the platform received 2.4 million virtual visits in 2021—up from 1.6 million in 2020, according to a Q4 2021 earnings report released on the company's website.

This boost in growth comes from a slew of 2021 marketing initiatives, including increasing its marketing investment in Q3 and Q4 to boost customer acquisition, partnering with well-known retailers such as Amazon and Revolve to scale its online and in-person sales, and shifting its pharmacy fulfillment services in-house to offer consumers more affordable, subscription-based healthcare.

"D2C healthcare companies are on a growth tear—Hims & Hers is just one of the most notable key players," said Rhea Patel, analyst at Insider Intelligence. While widespread marketing may continue to boost growth for the D2C healthcare segment, "D2C companies may have to deal with high customer acquisition costs compared with traditional providers who already have built-in channels (insurance) sending patients their way," added Patel.

Read This Full Story on Insider Intelligence
 

Related articles

 
Best Buy's Current Health is tapping Zoom to level up in telehealth
View Article
2 key areas where digital health can unlock wider access to mental health services
View Article
 

Thanks for Reading!

Find out why more than 100,000 corporate subscribers worldwide trust our unbiased approach to make grounded decisions about the future of their business.

Become a Client
 
 

Email sent to: nguyenvu1187.love5@blogger.com

Manage your email preferences  |  Unsubscribe  |  Terms of Service  |  Privacy Policy
 

© 2022 Insider Intelligence, 11 Times Square, New York, NY 10036

 
Powered By SailthrU
                                                           

0 comments:

Post a Comment